Voyager Therapeutics, Inc. (VYGR)
| Market Cap | 208.23M |
| Revenue (ttm) | 171.13M |
| Net Income (ttm) | 36.74M |
| Shares Out | 37.13M |
| EPS (ttm) | 0.98 |
| PE Ratio | 5.68 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $5.57 |
| Previous Close | $5.53 |
| Change ($) | 0.04 |
| Change (%) | 0.72% |
| Day's Open | 5.59 |
| Day's Range | 5.40 - 5.73 |
| Day's Volume | 327,312 |
| 52-Week Range | 5.18 - 14.62 |
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDA...
LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021
New York, New York--(Newsfile Corp. - March 3, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR)...
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...
NEW YORK, Feb. 27, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between Ju...
With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1...
CAMBRIDGE, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for patients...
LOS ANGELES, Feb. 25, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc....
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NAS...
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between Ju...
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...
LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between...
New York, New York--(Newsfile Corp. - February 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: V...
NEW YORK, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from Ju...
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe n...
New York, New York--(Newsfile Corp. - February 17, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: V...
NEW YORK, Feb. 16, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed against Voyager Therapeutics, Inc. ("V...
NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) betwe...
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VYGR #ClassAction--Shareholder rights law firm Robbins LLP reminds shareholders that a purchaser of Voyager Therapeutics, Inc. (Nasdaq: VYGR)...
New York, New York--(Newsfile Corp. - February 10, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (N...
Los Angeles, California--(Newsfile Corp. - February 10, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyag...
Investors with losses are encouraged to contact the firm before March 24, 2021; click here to submit trade information
NEW YORK, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between...
NEW YORK, Feb. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
New York, New York--(Newsfile Corp. - February 6, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NA...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1, 2017 and No...
NEW YORK, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutic...
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a announces that a federal securities class action lawsuit has been filed against Voyager Therap...
NEW YORK, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of Voyager Therapeutics, Inc. (NASDAQ: VYGR) from Ju...
Voyager Therapeutics (NASDAQ: VYGR) shares are trading lower Wednesday after the company announced that the FDA had notified Neurocrine that it placed a clinical hold on the RESTORE-1 clinical...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or "the Company") (NAS...
CAMBRIDGE, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that Neurocrine Biosciences, Inc. (Nasdaq: NBIX) provided notice of termination of...
NEW YORK, Jan. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voya...
LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021 LEAD PLAINTIFF DEADLINE IS MARCH 24, 2021
As of late, it has definitely been a great time to be an investor in Voyager Therapeutics (VYGR).
LOS ANGELES, Jan. 27, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Voyager Therapeutics, Inc....
LOS ANGELES--(BUSINESS WIRE)---- $VYGR #VYGR--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc.
New York, New York--(Newsfile Corp. - January 26, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NA...
NEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASD...
Atlanta, Georgia--(Newsfile Corp. - January 25, 2021) - Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Voyager Therapeutics, Inc...
SAN DIEGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VYGR #ClassAction--Voyager Therapeutics, Inc. (VYGR) Misled Shareholders Regarding the Viability of its Lead Clinical Candidate for Huntingto...
LOS ANGELES--(BUSINESS WIRE)---- $VYGR #VYGR--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Voyager Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Voyager Therapeutics, ...
NEW YORK, Jan. 23, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Voyager Therapeutics, Inc. ("Voyager" or the "Company") (NASDAQ: VYGR) and ce...
CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe n...
Investors need to pay close attention to Voyager (VYGR) stock based on the movements in the options market lately.
About VYGR
Voyager Therapeutics, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progr... [Read more...]
| Industry Biotechnology | IPO Date Nov 11, 2015 |
| CEO G. Andre Turenne | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol VYGR |
Analyst Forecasts
According to 13 analysts, the average rating for VYGR stock is "Buy." The 12-month stock price forecast is 10.25, which is an increase of 84.02% from the latest price.